Moderna Inc (NQ: MRNA )

65.20 -2.81 (-4.14%)

Streaming Delayed Price Updated: 11:34 AM EDT, Sep 20, 2024 Add to My Watchlist

Price and Volume

Volume	3,088,311
Open	67.60
Bid (Size)	65.20 (1)
Ask (Size)	65.22 (2)
Prev. Close	68.02
Today's Range	64.93 - 67.91
52wk Range	62.55 - 170.47
Shares Outstanding	384,000,000
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Pfizer Advances On Its Cancer Journey

Today 10:48 EDT

On Saturday, Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer cachexia during the European Society for Medical Oncology 2024...

Via Benzinga

Down 13% in 1 Day, Is Moderna Stock in Trouble?

Today 5:52 EDT

There's no hope of it recovering to its prior heights anytime soon.

Via The Motley Fool

Performance

YTD	-42.04%	-42.04%
1 Month	-25.00%	-25.00%
3 Month	-51.48%	-51.48%
6 Month	-37.36%	-37.36%
1 Year	-37.02%	-37.02%

More News

3 Beaten-Down Stocks Ready for a Comeback

September 19, 2024

Via MarketBeat

Novo Nordisk Just Took a $530 Million Step Onto Moderna's Turf. Here's What It Means for Both Stocks

September 19, 2024

Via The Motley Fool

Moderna, Inc. REMINDER – MRNA Stockholders Should Contact Robbins LLP for Information About the Moderna, Inc. Class Action and Pending Lead Plaintiff Deadline

September 18, 2024

From Robbins LLP

Via GlobeNewswire

16 Analysts Have This To Say About Moderna

September 13, 2024

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session

September 18, 2024

Via Benzinga

Jim Cramer Labels Moderna A 'Big Disappointment,' But Suggests Doubling Down On Another Pharma Powerhouse

September 18, 2024

Via Benzinga

Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030

September 18, 2024

Via The Motley Fool

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, Lululemon, XPEL, and Nano Nuclear and Encourages Investors to Contact the Firm

September 17, 2024

From Bragar Eagel & Squire

Via GlobeNewswire

S&P 500 Briefly Hits Record High Just Ahead Of Fed Rate Cut, Extends 7-Day Winning Streak: Tuesday's Top 5 Gainers

September 17, 2024

Via Benzinga

Momentum Investing Gives You An Edge, Until It Doesn’t

September 17, 2024

Via Talk Markets

Small Caps, Bitcoin Rally As Traders Await Fed Rate Cut; Treasury Yields, US Dollar Tick Up On Strong Retail Sales: What's Driving Markets Tuesday?

September 17, 2024

Via Benzinga

What's Going On With Moderna Shares Tuesday?

September 17, 2024

Via Benzinga

Moderna Receives Health Canada Approval For Updated COVID-19 Vaccine Targeting KP.2 Variant Of SARS-COV-2 For Ages Six Months And Older

September 17, 2024

Via ACCESSWIRE

MODERNA, INC. (NASDAQ: MRNA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Moderna, Inc. Investors of Upcoming Deadline

September 16, 2024

From Bernstein Liebhard LLP

Via GlobeNewswire

DeSantis Administration Cautions Against Pfizer, Moderna mRNA Covid Vaccines for Vulnerable Individuals, Cites Concerns Related To Rare Heart Conditions

September 16, 2024

Via Benzinga

Moderna’s Recent Drop: 4 Reasons Bulls See Opportunity

September 16, 2024

Via MarketBeat

Moderna, Tyson Foods And Adobe Are Among Top 10 Large Cap Stock Losers Last Week (Sep 8-Sep 14): Are The Others In Your Portfolio?

September 15, 2024

Via Benzinga

Down More Than 50%, Is It Time to Buy Moderna Stock as the Biotech Charts a New Post-COVID Path?

September 15, 2024

Via The Motley Fool

Wall Street's Top 10 Stock Calls This Week - Saturday, Sept. 14

September 14, 2024

Via Talk Markets

Investing in Biotech or Pharma Stocks? Pay Attention to These 3 Things and You'll Win More

September 14, 2024

Via The Motley Fool

After Moderna's Shocking News, Is the Stock a Buy or a Sell?

September 14, 2024

Via The Motley Fool

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, Lululemon, XPEL, and Nano Nuclear and Encourages Investors to Contact the Firm

September 13, 2024

From Bragar Eagel & Squire

Via GlobeNewswire

Moderna Faces Analyst Downgrades Amid Revised R&D Restructured Strategy and Delayed Profitability Target

September 13, 2024

Via Benzinga

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

RESOURCES

CLARION ENERGY MEDIA

POWER & ENERGY EVENT SERIES

Moderna Inc (NQ: MRNA )

Price and Volume

Top News

Performance

More News